Over 500 UK patients gain early access to new melanoma treatment

Medicines and Healthcare products Regulatory Agency

December 23
10:00 2015

MSD (known as Merck & Co Inc. in the United States and Canada) worked with the MHRA (Medicines and Healthcare products Regulatory Agency) to take the new skin cancer treatment pembrolizumab through the early access to medicines scheme (EAMS). The successful application has led to over 500 patients with advanced melanoma benefiting from the breakthrough treatment before being licensed.

Pembrolizumab was the first medicine to be awarded a positive scientific opinion, which helped to accelerate access to the drug by around 4 months.

Ben Lucas, Business Unit Director, Oncology, MSD said:

EAMS undoubtedly accelerated access to pembrolizumab for patients with advanced melanoma and demonstrates a world-leading example of how healthcare agencies and industry can work together to get treatments to patients more quickly.

EAMS aims to give patients with life threatening or seriously debilitating conditions access to medicines that are not licensed yet when there is a clear unmet medical need. See our guidance on EAMS for more information.

Dr Siu Ping Lam, Director of Licensing, MHRA said:

EAMS is an important step in ensuring patients gain access to innovative medicines as soon as possible, improving health outcomes in patients that urgently need new treatments.

MSDs decision to submit Pembrolizumab meant that we awarded our first positive opinion ahead of a licensing decision, thoroughly tested EAMS principles and processes, and learned much along the way.

Speeding up patient access to new, promising, innovative treatments is a current priority for UK government, regulatory agencies and the pharmaceutical industry.

See the full case study for more information and contact the Innovation Office to find out more about accessing expert knowledge, guidance and experience that could help you develop ideas as well as save time and money #HealthInnovation #MHRAinnovation

Related Articles


  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:

Post my comment

Recent Comments

Follow Us on Twitter

Share This

Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: